Dr. David Wellis, CEO of San Diego Blood Bank, is the speaker for the September 7 meeting
The recent FDA approval of Kymriah to treat certain types of leukemia in children and young adults highlights the growing importance of personalized and precision medicine. Dr. David Wellis, CEO of the San Diego Blood Bank (SDBB), will discuss how SDBB resources are being applied to precision medicine to develop new, personalized treatments for a variety of diseases.
Dr. Wellis received his B.S. from UC Irvine and both a M.S. and Ph.D. from Emory University, where his research focused on the biophysical mechanisms of olfactory function. He undertook postdoctoral research at Tufts University and UC Berkeley, as well as business training at Santa Clara University and UC Berkeley. His experience in basic research forms the foundation for the involvement of SDBB with the extensive biotechnology community in San Diego and southern California.